|
May 27
|
Sector Update: Health Care Stocks Rise Premarket Tuesday
|
|
May 27
|
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
|
|
May 27
|
BeiGene Says EU Panel Recommends Tevimbra as Treatment for Nasopharyngeal Cancer
|
|
May 27
|
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
|
|
May 22
|
Exploring US High Growth Tech Stocks In May 2025
|
|
May 22
|
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors
|
|
Apr 5
|
BeiGene (NasdaqGS:ONC) Gains 32% In A Quarter Amid Positive EMA Opinion On TEVIMBRA
|
|
Feb 17
|
HRMY or ONC: Which Is the Better Value Stock Right Now?
|
|
Feb 13
|
BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27
|
|
Feb 12
|
Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:ONC) 41% Undervaluation?
|
|
Dec 30
|
BeiGene’s Tevimbra approved in US for first-line gastric cancer treatment
|